Physician profile
Paul Duru
NPI 1487116950
$2,721.32
in general payments reported to CMS, 2019-2025
17 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,187 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878 · Grant: $682 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.83 |
| Grant | $682.00 |
| Education | $161.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $682.00 | 2024 | |
| Medtronic, INC. | $393.29 | 2024-2025 | Ffrangio, Onyx Frontier, Symplicity G3 |
| Abiomed | $290.53 | 2024-2025 | Impella |
| Kestra Medical Technology Services, INC. | $240.69 | 2024-2025 | Assure Wcd |
| Abbott Laboratories | $172.94 | 2025 | Cardiomems |
| Edwards Lifesciences Corporation | $151.05 | 2025 | |
| Cvrx, INC. | $148.91 | 2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $123.15 | 2025 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $122.09 | 2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $121.96 | 2025 | Camzyos |
| Lantheus Medical Imaging, INC. | $87.68 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $63.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.76 | 2025 | |
| Biosense Webster, INC. | $34.38 | 2025 | Carto 3 |
| Novo Nordisk INC | $21.84 | 2025 | Wegovy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $17.34 | 2025 | Cleviprex, Kengreal |
| Glaxosmithkline, LLC. | $13.71 | 2025 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Duru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.